Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Profitability Ratios
Quarterly Data

Beginner level

Profitability Ratios (Summary)

Gilead Sciences Inc., profitability ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Return on Sales
Gross profit margin 81.23% 78.72% 78.25% 79.06% 78.86% 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77%
Operating profit margin 16.72% 11.01% -4.40% 19.89% 19.38% 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87%
Net profit margin 0.51% 5.56% -1.18% 22.17% 24.35% 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07%
Return on Investment
Return on equity (ROE) 0.68% 7.27% -1.43% 22.49% 23.91% 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48%
Return on assets (ROA) 0.18% 2.08% -0.46% 8.31% 8.74% 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70%

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Gilead Sciences Inc.’s gross profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Gilead Sciences Inc.’s operating profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Gilead Sciences Inc.’s net profit margin ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Gilead Sciences Inc.’s ROE improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level.
ROA A profitability ratio calculated as net income divided by total assets. Gilead Sciences Inc.’s ROA improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level.

Gross Profit Margin

Gilead Sciences Inc., gross profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Gross profit on product sales 5,930  5,352  4,003  4,498  4,113  4,481  4,607  4,243  4,111  4,369  4,344  4,000  4,581  5,370  5,920  5,420  6,141  6,276  6,787  6,488 
Product sales 7,328  6,493  5,067  5,467  5,796  5,516  5,607  5,200  5,681  5,455  5,540  5,001  5,837  6,402  7,046  6,377  7,216  7,405  7,651  7,681 
Profitability Ratio
Gross profit margin1 81.23% 78.72% 78.25% 79.06% 78.86% 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77%
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 50.49% 50.18% 50.97% 52.13% 52.46% 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09%
AbbVie Inc. 66.41% 68.74% 73.56% 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25%
Amgen Inc. 74.59% 75.55% 77.15% 78.90% 80.38% 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33% 81.37% 81.26% 81.05% 80.99%
Bristol-Myers Squibb Co. 72.31% 71.18% 69.47% 68.02% 69.10% 69.90% 70.10% 70.86% 70.98% 70.37% 70.12% 69.62% 70.80% 71.92% 72.78% 74.19% 74.54%
Eli Lilly & Co. 77.66% 78.26% 78.67% 79.22% 78.85% 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35%
Illumina Inc. 68.01% 69.02% 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48%
Johnson & Johnson 65.58% 65.68% 65.66% 66.15% 66.42% 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84% 68.20% 69.35% 69.88% 69.84%
Merck & Co. Inc. 67.74% 71.23% 70.06% 70.11% 69.87% 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10%
Pfizer Inc. 79.26% 79.86% 79.94% 79.94% 80.25% 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61% 78.66% 78.15% 77.28% 76.66%
Regeneron Pharmaceuticals Inc. 86.82% 87.98% 88.21% 89.72% 90.05% 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83%
Vertex Pharmaceuticals Inc. 88.14% 88.01% 87.71% 87.24% 86.84% 86.60% 86.56% 86.74% 86.56% 86.88% 87.31% 87.59% 88.95% 89.04% 89.08% 89.76% 87.64%
Zoetis Inc. 69.18% 69.64% 69.73% 69.51% 68.18% 67.38% 66.92% 66.49% 67.19% 68.12% 68.04% 67.31% 66.55% 65.14% 64.91% 65.30% 65.92%

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Q4 2020 Calculation
Gross profit margin = 100 × (Gross profit on product salesQ4 2020 + Gross profit on product salesQ3 2020 + Gross profit on product salesQ2 2020 + Gross profit on product salesQ1 2020) ÷ (Product salesQ4 2020 + Product salesQ3 2020 + Product salesQ2 2020 + Product salesQ1 2020)
= 100 × (5,930 + 5,352 + 4,003 + 4,498) ÷ (7,328 + 6,493 + 5,067 + 5,467) = 81.23%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Gilead Sciences Inc.’s gross profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Operating Profit Margin

Gilead Sciences Inc., operating profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Income (loss) from operations 2,651  2,001  (2,983) 2,402  1,093  (1,473) 2,430  2,237  1,144  2,623  2,280  2,153  2,291  3,812  4,254  3,767  4,045  4,399  4,538  4,651 
Product sales 7,328  6,493  5,067  5,467  5,796  5,516  5,607  5,200  5,681  5,455  5,540  5,001  5,837  6,402  7,046  6,377  7,216  7,405  7,651  7,681 
Profitability Ratio
Operating profit margin1 16.72% 11.01% -4.40% 19.89% 19.38% 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 15.48% 13.39% 12.78% 14.18% 14.21% 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27%
AbbVie Inc. 24.81% 28.45% 30.17% 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60%
Amgen Inc. 37.70% 38.59% 39.76% 41.89% 43.57% 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76% 46.66% 46.93% 45.68% 44.74%
Bristol-Myers Squibb Co. -21.60% 9.27% 11.67% 16.30% 22.62% 28.63% 28.59% 23.43% 22.69% 18.64% 15.93% 17.50% 17.39% 19.71% 21.73% 24.06% 23.83%
Eli Lilly & Co. 24.69% 23.55% 24.48% 25.64% 22.29% 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30%
Illumina Inc. 17.91% 22.08% 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48%
Johnson & Johnson 23.60% 24.30% 24.64% 25.62% 24.15% 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07% 27.02% 28.55% 28.83% 28.72%
Merck & Co. Inc. 16.47% 26.87% 25.40% 25.49% 24.77% 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51%
Pfizer Inc. 19.47% 24.77% 23.75% 25.38% 25.46% 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92% 24.69% 23.57% 22.94% 22.73%
Regeneron Pharmaceuticals Inc. 42.09% 37.43% 34.64% 30.45% 28.10% 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38%
Vertex Pharmaceuticals Inc. 46.03% 44.43% 38.67% 34.05% 28.77% 21.38% 25.48% 23.98% 20.84% 22.38% 3.87% -0.77% 4.95% 1.62% 16.16% 14.62% 0.58%
Zoetis Inc. 33.62% 33.87% 33.36% 32.72% 31.42% 31.01% 29.80% 30.05% 31.12% 33.00% 33.86% 33.02% 32.15% 29.43% 28.34% 28.55% 28.48%

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Q4 2020 Calculation
Operating profit margin = 100 × (Income (loss) from operationsQ4 2020 + Income (loss) from operationsQ3 2020 + Income (loss) from operationsQ2 2020 + Income (loss) from operationsQ1 2020) ÷ (Product salesQ4 2020 + Product salesQ3 2020 + Product salesQ2 2020 + Product salesQ1 2020)
= 100 × (2,651 + 2,001 + -2,983 + 2,402) ÷ (7,328 + 6,493 + 5,067 + 5,467) = 16.72%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Gilead Sciences Inc.’s operating profit margin ratio improved from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Net Profit Margin

Gilead Sciences Inc., net profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead 1,551  360  (3,339) 1,551  2,696  (1,165) 1,880  1,975  2,097  1,817  1,538  (3,865) 2,718  3,073  2,702  3,108  3,330  3,497  3,566 
Product sales 7,328  6,493  5,067  5,467  5,796  5,516  5,607  5,200  5,681  5,455  5,540  5,001  5,837  6,402  7,046  6,377  7,216  7,405  7,651  7,681 
Profitability Ratio
Net profit margin1 0.51% 5.56% -1.18% 22.17% 24.35% 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 12.99% 10.50% 9.89% 11.15% 11.56% 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71%
AbbVie Inc. 10.08% 18.16% 19.20% 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22%
Amgen Inc. 29.97% 30.91% 31.53% 33.64% 35.32% 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08% 37.36% 37.24% 36.12% 35.27%
Bristol-Myers Squibb Co. -21.20% -0.11% -1.61% 3.08% 13.15% 23.39% 26.00% 22.09% 21.81% 6.50% 1.74% 4.37% 4.85% 20.56% 22.66% 24.22% 22.94%
Eli Lilly & Co. 25.24% 24.01% 24.48% 23.97% 37.27% 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90%
Illumina Inc. 20.25% 19.70% 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29%
Johnson & Johnson 17.82% 21.01% 18.86% 20.75% 18.42% 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70% 21.28% 22.52% 22.87% 23.01%
Merck & Co. Inc. 14.72% 24.33% 22.20% 21.10% 21.01% 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85%
Pfizer Inc. 22.95% 17.85% 28.80% 31.17% 31.45% 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55% 18.69% 15.90% 13.88% 13.66%
Regeneron Pharmaceuticals Inc. 41.35% 38.28% 37.30% 28.56% 26.91% 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42%
Vertex Pharmaceuticals Inc. 43.70% 44.91% 38.51% 31.35% 28.27% 59.23% 64.13% 66.01% 68.80% 22.87% 15.84% 9.36% 10.59% 8.53% 12.19% 8.78% -6.58%
Zoetis Inc. 24.54% 25.42% 25.50% 25.41% 23.96% 23.76% 22.74% 23.47% 24.52% 20.35% 19.95% 17.97% 16.28% 18.29% 17.50% 17.25% 16.80%

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Q4 2020 Calculation
Net profit margin = 100 × (Net income (loss) attributable to GileadQ4 2020 + Net income (loss) attributable to GileadQ3 2020 + Net income (loss) attributable to GileadQ2 2020 + Net income (loss) attributable to GileadQ1 2020) ÷ (Product salesQ4 2020 + Product salesQ3 2020 + Product salesQ2 2020 + Product salesQ1 2020)
= 100 × (1,551 + 360 + -3,339 + 1,551) ÷ (7,328 + 6,493 + 5,067 + 5,467) = 0.51%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Gilead Sciences Inc.’s net profit margin ratio improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level.

Return on Equity (ROE)

Gilead Sciences Inc., ROE calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead 1,551  360  (3,339) 1,551  2,696  (1,165) 1,880  1,975  2,097  1,817  1,538  (3,865) 2,718  3,073  2,702  3,108  3,330  3,497  3,566 
Total Gilead stockholders’ equity 18,202  17,445  18,027  22,067  22,525  20,604  22,616  21,951  21,387  22,861  21,672  20,591  20,442  24,845  22,677  20,441  18,887  16,868  15,536  13,398 
Profitability Ratio
ROE1 0.68% 7.27% -1.43% 22.49% 23.91% 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48%
Benchmarks
ROE, Competitors2
Abbott Laboratories 13.71% 10.78% 10.17% 11.84% 11.86% 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82%
AbbVie Inc. 35.30% 48.34% 47.30% 179.59% 104.16% 99.42% 110.08% 126.25% 128.41%
Amgen Inc. 77.20% 67.09% 68.48% 80.92% 81.07% 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84% 25.37% 25.77% 25.76% 25.85%
Bristol-Myers Squibb Co. -23.84% -0.09% -1.15% 1.91% 6.66% 32.04% 38.65% 33.80% 35.07% 10.50% 3.05% 7.18% 8.58% 28.61% 31.20% 33.55% 27.55%
Eli Lilly & Co. 109.79% 115.45% 137.26% 179.72% 319.09% 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54%
Illumina Inc. 13.98% 13.57% 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06%
Johnson & Johnson 23.25% 26.35% 24.11% 28.01% 25.42% 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16% 21.39% 22.71% 23.46% 23.49%
Merck & Co. Inc. 27.91% 39.47% 37.91% 38.72% 37.99% 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78%
Pfizer Inc. 15.21% 13.31% 22.02% 24.28% 25.77% 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88% 16.14% 14.26% 12.49% 12.12%
Regeneron Pharmaceuticals Inc. 31.86% 31.17% 32.94% 18.79% 19.08% 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13%
Vertex Pharmaceuticals Inc. 31.22% 33.08% 27.67% 23.38% 19.34% 40.81% 43.70% 45.63% 47.28% 22.27% 15.46% 9.41% 12.99% 10.93% 15.55% 11.82% -9.69%
Zoetis Inc. 43.46% 46.17% 54.23% 58.52% 55.39% 54.56% 57.03% 59.91% 65.35% 54.96% 56.60% 49.90% 48.81% 47.11% 51.20% 53.14% 55.21%

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Q4 2020 Calculation
ROE = 100 × (Net income (loss) attributable to GileadQ4 2020 + Net income (loss) attributable to GileadQ3 2020 + Net income (loss) attributable to GileadQ2 2020 + Net income (loss) attributable to GileadQ1 2020) ÷ Total Gilead stockholders’ equity
= 100 × (1,551 + 360 + -3,339 + 1,551) ÷ 18,202 = 0.68%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Gilead Sciences Inc.’s ROE improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level.

Return on Assets (ROA)

Gilead Sciences Inc., ROA calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in millions)
Net income (loss) attributable to Gilead 1,551  360  (3,339) 1,551  2,696  (1,165) 1,880  1,975  2,097  1,817  1,538  (3,865) 2,718  3,073  2,702  3,108  3,330  3,497  3,566 
Total assets 68,407  60,878  55,934  59,741  61,627  59,146  63,210  62,837  63,675  64,305  65,355  65,381  70,283  64,662  60,263  57,701  56,977  56,609  49,980  47,765 
Profitability Ratio
ROA1 0.18% 2.08% -0.46% 8.31% 8.74% 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70%
Benchmarks
ROA, Competitors2
Abbott Laboratories 6.20% 4.90% 4.52% 5.36% 5.43% 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66%
AbbVie Inc. 3.07% 4.93% 4.65% 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01%
Amgen Inc. 11.54% 11.37% 11.23% 12.45% 13.13% 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48% 10.18% 10.27% 10.14% 9.95%
Bristol-Myers Squibb Co. -7.61% -0.04% -0.44% 0.74% 2.65% 9.85% 11.24% 14.77% 14.06% 4.24% 1.15% 2.78% 3.00% 12.45% 13.73% 14.68% 13.22%
Eli Lilly & Co. 13.28% 12.68% 13.39% 13.46% 21.17% 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05%
Illumina Inc. 8.65% 8.62% 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81%
Johnson & Johnson 8.41% 9.95% 9.59% 11.07% 9.59% 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83% 10.17% 10.69% 11.39% 11.71%
Merck & Co. Inc. 7.72% 12.83% 11.56% 11.95% 11.66% 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11%
Pfizer Inc. 6.23% 4.85% 7.96% 9.49% 9.72% 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40% 5.70% 4.94% 4.32% 4.20%
Regeneron Pharmaceuticals Inc. 20.47% 19.62% 20.68% 14.46% 14.29% 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84%
Vertex Pharmaceuticals Inc. 23.07% 23.81% 20.37% 16.99% 14.15% 28.53% 31.50% 32.94% 33.57% 14.00% 9.58% 5.72% 7.43% 6.12% 7.91% 6.02% -3.87%
Zoetis Inc. 12.04% 12.12% 12.37% 13.97% 12.99% 12.96% 12.52% 12.75% 13.25% 11.13% 12.96% 11.25% 10.06% 10.09% 11.25% 11.18% 10.73%

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Q4 2020 Calculation
ROA = 100 × (Net income (loss) attributable to GileadQ4 2020 + Net income (loss) attributable to GileadQ3 2020 + Net income (loss) attributable to GileadQ2 2020 + Net income (loss) attributable to GileadQ1 2020) ÷ Total assets
= 100 × (1,551 + 360 + -3,339 + 1,551) ÷ 68,407 = 0.18%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Gilead Sciences Inc.’s ROA improved from Q2 2020 to Q3 2020 but then slightly deteriorated from Q3 2020 to Q4 2020 not reaching Q2 2020 level.